Vaccine development for infectious diseases

Some infectious diseases require unique modifications to the traditional vaccine development approach.  

Traditional vaccine development and approval take approximately 10-15 years. While the development of the SARS-CoV-2 vaccine met an unprecedented pace, modifying the traditional vaccine development process is not unusual. Throughout history, other viral epidemics have demanded unique approaches to vaccine development and flexibility in approval timelines. 

Download this poster from Drug Discovery News to learn about traditional vaccine development and discover how epidemic-level infectious diseases have modified the vaccine development landscape.

Supported by